← All trials
NCT00168181
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2002
- Primary completion
- —
- Completion date
- Apr 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 220
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- University of CalgaryLead sponsor
- CancerCare ManitobaCollaborator
- McGill UniversityCollaborator
- University of OttawaCollaborator
- University of CalgaryOverall official - principal investigator
- Newfoundland Cancer Treatment & Research FoundationCollaborator
- Notre-Dame Hospital, ParisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.